enGene Holdings

ENGN

Market cap $581M

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene”), a clinical-stage, non-viral genetic medicines company, today announced that management will participate in the following investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference Date: Thursday, February 26, 2026 Format: Presentation Time: 1:20 p.m. ET Leerink Partners 2026 Global Healthcare Conference Date: Monday, March 9, 2026 Format: Fireside chat Time: 8:00 a.m. ET Barclays 28th Ann.

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene”), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 2:30 p.m. ET. A live webcast of the fireside chat can be accessed on the "Events and Presentations” page under the “Investors” section of the enGene website at.

enGene Holdings (ENGN) maintains a Buy rating, driven by positive preliminary data and two major catalysts expected in 2H 2026. ENGN's detalimogene gene therapy achieved a 62% 6-month complete response rate in BCG-unresponsive, high-risk NMIBC with CIS post-amendment. ENGN is positioned as a potential first-line, best-in-class option for BCG-unresponsive NMIBC, offering ease of use and strong tolerability.

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it has entered into an amendment to an amended and restated loan and security agreement (as amended, the “Loan Agreement”) with two of its subsidiaries and Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”), as agent, for up to US$125 million. Access to the additional non-dilutive capital strengthens enGene's balance sheet.

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the full year ended October 31, 2025, and provided a business update. “We are closing 2025 in a position of strength: enrollment in LEGEND's pivotal cohort is complete and the recent data update from the LEGEND pivotal cohort supports an emerging, competitive profile for the use of detalimogene as the.

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that the U.S. Food and Drug Administration (FDA) has selected detalimogene voraplasmid (also known as detalimogene and previously EG-70) to participate in the Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) Program. Detalimogene is a novel, investigational, non-viral gene therapy for patie.

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene”), a clinical-stage, non-viral genetic medicines company, today announced that Alex Nichols, Ph.D., Chief Strategy and Operations Officer, will present at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025, at 12:10 p.m. ET. A webcast of the presentation can be accessed on the "Events and Presentations” page under the “Investors” section of the enGene website at www.engene.com and wil.

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced the pricing of its previously announced underwritten public offering of 12,558,823 common shares at a public offering price of $8.50 per share and pre-funded warrants to purchase 2,735,295 shares of its common shares at an offering price of $8.4999 per pre-funded warrant, in each case, before underwriting discounts and commiss.

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it has commenced an underwritten public offering of its common shares. All common shares to be sold in the offering will be offered by enGene. In addition, enGene intends to grant the underwriters a 30-day option to purchase up to a number of additional common shares equal to 15% of the total number of common shares sold.

enGene Holdings remains a Buy, driven by promising LEGEND trial data for detalimogene voraplasmid in non-muscle invasive bladder cancer. ENGN's phase 2 LEGEND trial showed a 63% complete response rate, comparable to ImmunityBio's Anktiva, positioning ENGN as a strong NMIBC contender. ENGN has a robust cash runway into 2027, supporting continued operations and potential approval without immediate fundraising concerns.